Compare Eli Lilly And Co (LLY) vs Zillow Group Inc Class A (ZG) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

Zillow Group (ZG) trades at $32.84, down 2.58% on the day, amid a bearish technical signal and ongoing securities class action lawsuits. The company reported revenue of $2.58B in 2025 with a net income of $23M, marking a return to profitability after losses in prior years. Analyst consensus is a Buy with a $57.80 price target, but recent news highlights legal risks from alleged anticompetitive practices.

The outlook is mixed: strong fundamentals with improving margins and revenue growth support upside potential, but legal overhangs and bearish technicals pose near-term risks. Investors should weigh the high P/E ratio of 134.8 against earnings beats and analyst optimism for long-term recovery.